JP2003512327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003512327A5 JP2003512327A5 JP2001531388A JP2001531388A JP2003512327A5 JP 2003512327 A5 JP2003512327 A5 JP 2003512327A5 JP 2001531388 A JP2001531388 A JP 2001531388A JP 2001531388 A JP2001531388 A JP 2001531388A JP 2003512327 A5 JP2003512327 A5 JP 2003512327A5
- Authority
- JP
- Japan
- Prior art keywords
- sodium
- hydrogen
- stable liquid
- alkyl
- potassium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 150000002431 hydrogen Chemical group 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical group 0.000 description 8
- 229940121819 ATPase inhibitor Drugs 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012669 liquid formulation Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- -1 alkoxythio Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000002071 phenylalkoxy group Chemical group 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903831A SE9903831D0 (sv) | 1999-10-22 | 1999-10-22 | Formulation of substituted benzimidazoles |
| SE9903831-7 | 1999-10-22 | ||
| PCT/SE2000/001992 WO2001028558A1 (en) | 1999-10-22 | 2000-10-13 | Formulation of substituted benzimidazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512327A JP2003512327A (ja) | 2003-04-02 |
| JP2003512327A5 true JP2003512327A5 (enExample) | 2007-11-15 |
Family
ID=20417464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001531388A Pending JP2003512327A (ja) | 1999-10-22 | 2000-10-13 | 置換ベンズイミダゾール製剤 |
Country Status (35)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002012225A1 (en) * | 2000-08-04 | 2002-02-14 | Takeda Chemical Industries, Ltd. | Salts of benzimidazole compound and use thereof |
| EP1310252A4 (en) * | 2000-08-18 | 2009-06-10 | Takeda Pharmaceutical | INJECTIONS |
| MY137726A (en) * | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
| GB2376231A (en) * | 2001-06-06 | 2002-12-11 | Cipla Ltd | Benzimidazole-cyclodextrin inclusion complex |
| FR2845915B1 (fr) * | 2002-10-21 | 2006-06-23 | Negma Gild | Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien |
| FR2845916B1 (fr) * | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine |
| FR2845917B1 (fr) * | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire |
| FR2848555B1 (fr) * | 2002-12-16 | 2006-07-28 | Negma Gild | Enantiomere(-)du tenatoprazole et son application en therapeutique |
| KR20050123096A (ko) * | 2003-02-24 | 2005-12-29 | 미쯔비시 웰 파마 가부시키가이샤 | 테나토프라졸의 거울상 이성질체 및 치료를 위한 그 용도 |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| US20060089376A1 (en) * | 2004-10-27 | 2006-04-27 | Joshi Ramesh A | Tenatoprazole salts and process of preparation thereof |
| BRPI0711048A2 (pt) * | 2006-05-09 | 2011-08-23 | Astrazeneca Ab | formulações parenteral esterilizada e sólida estáveis, solução para administração parenteral, processos para a preparação de uma formulação e para a fabricação de um produto, método para prevenir ou tratar doenças gastrintestinais, uso de uma formulação sólida estável |
| CN100411613C (zh) * | 2006-12-08 | 2008-08-20 | 中国药科大学 | 一种奥美拉唑速释固体制剂及其制备方法 |
| WO2016077185A1 (en) | 2014-11-13 | 2016-05-19 | 3M Innovative Properties Company | Kit comprising atp-diphosphohydrolase for detecting bacterial atp in a sample |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| WO2025078989A1 (en) * | 2023-10-11 | 2025-04-17 | Reena Patel | Stabilized pharmaceutical compositions |
| WO2025181379A1 (en) * | 2024-03-01 | 2025-09-04 | Etico Lifesciences Private Limited | Liquid, storage stable, directly injectable, pantoprazole formulations, their uses and manufacturing |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| DK399389A (da) * | 1988-08-18 | 1990-02-19 | Takeda Chemical Industries Ltd | Injicerbare oploesninger |
| JP2536173B2 (ja) * | 1988-08-18 | 1996-09-18 | 武田薬品工業株式会社 | 注射剤 |
| KR930000861B1 (ko) | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
| ATE144421T1 (de) | 1992-07-28 | 1996-11-15 | Astra Ab | Injizierbares arzneimittel und satz, die omoprazol oder verwandte verbindungenenthalten |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| TW359614B (en) | 1993-08-31 | 1999-06-01 | Takeda Chemical Industries Ltd | Composition containing benzimidazole compounds for rectal administration |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US5877205A (en) | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
| SE510643C2 (sv) | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
| US6287594B1 (en) * | 1998-01-20 | 2001-09-11 | Edward S. Wilson | Oral liquid compositions |
-
1999
- 1999-10-22 SE SE9903831A patent/SE9903831D0/xx unknown
-
2000
- 2000-10-06 AR ARP000105283A patent/AR029005A1/es unknown
- 2000-10-09 TW TW089121063A patent/TWI236372B/zh not_active IP Right Cessation
- 2000-10-13 HU HU0203121A patent/HUP0203121A3/hu unknown
- 2000-10-13 SI SI200030759T patent/SI1274427T1/sl unknown
- 2000-10-13 JP JP2001531388A patent/JP2003512327A/ja active Pending
- 2000-10-13 EE EEP200200204A patent/EE05175B1/xx not_active IP Right Cessation
- 2000-10-13 EP EP00973295A patent/EP1274427B1/en not_active Expired - Lifetime
- 2000-10-13 SK SK539-2002A patent/SK286266B6/sk not_active IP Right Cessation
- 2000-10-13 AU AU11823/01A patent/AU782866B2/en not_active Ceased
- 2000-10-13 CZ CZ20021375A patent/CZ20021375A3/cs unknown
- 2000-10-13 TR TR2002/01103T patent/TR200201103T2/xx unknown
- 2000-10-13 UA UA2002043345A patent/UA74347C2/uk unknown
- 2000-10-13 AT AT00973295T patent/ATE304851T1/de active
- 2000-10-13 WO PCT/SE2000/001992 patent/WO2001028558A1/en not_active Ceased
- 2000-10-13 NZ NZ518155A patent/NZ518155A/en unknown
- 2000-10-13 KR KR1020027005112A patent/KR100785603B1/ko not_active Expired - Fee Related
- 2000-10-13 DE DE60022789T patent/DE60022789T2/de not_active Expired - Lifetime
- 2000-10-13 IL IL14910700A patent/IL149107A0/xx active IP Right Grant
- 2000-10-13 RU RU2002110328/15A patent/RU2286782C2/ru not_active IP Right Cessation
- 2000-10-13 DK DK00973295T patent/DK1274427T3/da active
- 2000-10-13 CN CNB008146373A patent/CN1213751C/zh not_active Expired - Fee Related
- 2000-10-13 CA CA2425199A patent/CA2425199C/en not_active Expired - Fee Related
- 2000-10-13 PL PL354926A patent/PL199868B1/pl not_active IP Right Cessation
- 2000-10-13 ES ES00973295T patent/ES2246903T3/es not_active Expired - Lifetime
- 2000-10-13 BR BR0014895-4A patent/BR0014895A/pt not_active IP Right Cessation
- 2000-10-13 MX MXPA02003900A patent/MXPA02003900A/es active IP Right Grant
- 2000-10-13 US US09/701,714 patent/US6730685B1/en not_active Expired - Fee Related
- 2000-10-19 MY MYPI20004932A patent/MY131971A/en unknown
- 2000-10-19 CO CO00079671A patent/CO5261533A1/es active IP Right Grant
-
2002
- 2002-04-10 BG BG106602A patent/BG65580B1/bg unknown
- 2002-04-11 IL IL149107A patent/IL149107A/en not_active IP Right Cessation
- 2002-04-12 ZA ZA200202905A patent/ZA200202905B/en unknown
- 2002-04-17 IS IS6347A patent/IS2196B/is unknown
- 2002-04-19 NO NO20021860A patent/NO329545B1/no not_active IP Right Cessation
-
2005
- 2005-12-19 CY CY20051101567T patent/CY1106055T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003512327A5 (enExample) | ||
| RU2002110328A (ru) | Препарат замещенных бензимидазолов | |
| RU2365588C2 (ru) | Хиназолиновые соединения | |
| JP2003500442A5 (enExample) | ||
| RU2000116011A (ru) | Пероральная фармацевтическая лекарственная форма с продолжительным высвобождением | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| JP2004505964A5 (enExample) | ||
| JP2004517099A5 (enExample) | ||
| CA2425199A1 (en) | Formulation of substituted benzimidazoles | |
| JP2005511531A5 (enExample) | ||
| ATE349432T1 (de) | 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer | |
| MY124864A (en) | Adenosine a2a receptor antagonists | |
| EP2269610A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| RU2006133898A (ru) | Производные бензимидазола и его применение | |
| EP2266569A3 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| JP2013513613A5 (enExample) | ||
| CA2170644A1 (en) | Multiple unit pharmaceutical preparation containing proton pump inhibitor | |
| JP2005505618A5 (enExample) | ||
| RU2001132139A (ru) | Имидазохинолины с сульфонамидными или сульфамидным замещением | |
| RU2003102612A (ru) | N-окиси в качестве пролекарств производных 4-фенилпиридина, являющихся натагонистами рецептора nk-1 | |
| JP2004506736A5 (enExample) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| JP2005530811A5 (enExample) | ||
| JP2004517098A5 (enExample) |